Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:15
Published online before print November 16, 2006, doi: 10.1161/01.STR.0000251696.12445.c4
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/1/15    most recent
01.STR.0000251696.12445.c4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaturvedi, S.
Right arrow Articles by Yadav, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaturvedi, S.
Right arrow Articles by Yadav, J. S.

(Stroke. 2007;38:15.)
© 2007 American Heart Association, Inc.


Letters to the Editor

Response to Letter by Kramer et al

Seemant Chaturvedi, MD

Wayne State University, Detroit, Mich

Jay S. Yadav, MD

Cleveland Clinic Foundation, Cleveland, Ohio

Response:

We would like to thank Dr Kramer and colleagues for their interest in our article. With regard to aspirin and extended release dipyridamole, we are aware of its effectiveness for long-term stroke prevention, and we did mention that use of aspirin and dipyridamole beyond the postprocedure period (>4 weeks) could decrease the rate of long-term stroke events. The reason we did not mention this agent in the immediate postprocedure period is that there is virtually no published data on use of aspirin and dipyridamole in carotid stenting patients. We encourage Dr Kramer and colleagues to publish their data, and if their initial results can be confirmed by other groups, then a randomized study would be appropriate.

With regard to glycoprotein IIbIIIa inhibitors, this is a more complicated area. The use of these potent medications has been clearly linked with cerebral hemorrhages in some case series reports.1 It is likely that the hemorrhage rate will vary according to several variables, including postprocedure blood pressure control, presence of recent infarction, etc. At the current time, use of these agents on a routine basis is controversial.2 Careful, controlled studies of these agents in well-defined populations of carotid stent patients are needed.

Acknowledgments

Disclosures

None.

References

  1. Wholey MH, Wholey MH, Tan WA, Toursarkissian B, Bailey S, Eles G, Jarmolowski C. Management of neurological complications of carotid artery stenting. J Endovasc Ther. 2001; 8: 341–353.[CrossRef][Medline] [Order article via Infotrieve]
  2. Xavier AR, Ionita CC, Kirmani JF, Qureshi AI. Controversies in endovascular therapy for carotid artery stenosis. In: Chaturvedi S, Rothwell PM, eds. Carotid Artery Stenosis: Current and Emerging Treatments. New York, NY: Taylor and Francis; 2005: 25–343.




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/1/15    most recent
01.STR.0000251696.12445.c4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chaturvedi, S.
Right arrow Articles by Yadav, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chaturvedi, S.
Right arrow Articles by Yadav, J. S.